Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.

[1]  Alberto Mantovani,et al.  Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.

[2]  K. O'Byrne,et al.  Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Kihara,et al.  Prognostic significance of endothelial Per-Arnt-sim domain protein 1/hypoxia-inducible factor-2alpha expression in a subset of tumor associated macrophages in invasive bladder cancer. , 2004, The Journal of urology.

[4]  J. Witjes.  Bladder carcinoma in situ in 2003: state of the art. , 2004, European urology.

[5]  J. Patard,et al.  T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. , 2001, The Journal of urology.

[6]  G. Steinberg,et al.  The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. , 2001, The Journal of urology.

[7]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[8]  M. Nakagawa,et al.  Prognostic value of tumor‐associated macrophage count in human bladder cancer , 2000, International journal of urology : official journal of the Japanese Urological Association.

[9]  Y. Luo,et al.  Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin. , 1999, Journal of immunology.

[10]  H. Kleinman,et al.  Tumor-associated macrophages as targets for cancer therapy. , 1998, Journal of the National Cancer Institute.

[11]  V A Kuznetsov,et al.  Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis. , 1998, The Journal of urology.

[12]  U. Studer,et al.  Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. , 1997, The Journal of urology.

[13]  A. Harris,et al.  Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. , 1996, Cancer research.

[14]  T. D. de Reijke,et al.  Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. , 1996, The Journal of urology.

[15]  D. Lamm,et al.  Long-term results of intravesical therapy for superficial bladder cancer. , 1992, The Urologic clinics of North America.

[16]  A. Mantovani,et al.  The origin and function of tumor-associated macrophages. , 1992, Immunology today.

[17]  P. Scardino,et al.  A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. , 1991, The New England journal of medicine.

[18]  T. Ratliff,et al.  Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin. , 1987, Cancer research.

[19]  S. Brosman.  The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ. , 1985, The Journal of urology.

[20]  M. Melicow.  Histological study of vesical urothelium intervening between gross neoplasms in total cystectomy. , 1952, The Journal of urology.